Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKonerandomized dose selection trial-Reference-Cited by-同舟云学术

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKonerandomized dose selection trial

Published:2015-04-20 Issue:3 Volume:170 Page:336-348
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Schey Steve¹,Brown Sarah R.²,Tillotson Avie-Lee²,Yong Kwee³,Williams Cathy⁴,Davies Faith⁵,Morgan Gareth⁵,Cavenagh Jamie⁶,Cook Gordon⁷,Cook Mark⁸,Orti Guillermo¹,Morris Curly⁹,Sherratt Debbie²,Flanagan Louise²,Gregory Walter²,Cavet James¹⁰,

Affiliation:

1. Department of Haematology; King's College Hospital; London UK

2. Leeds Institute of Clinical Trials Research; University of Leeds; Leeds UK

3. University College London Cancer Institute; London UK

4. Centre for Clinical Haematology; Nottingham University Hospitals; Nottingham UK

5. Haemato-Oncology Unit; Royal Marsden NHS Foundation Trust; Sutton UK

6. Department of Haematology; St Bartholomew's Hospital; London UK

7. Department of Haematology; St James's University Hospital; Leeds UK

8. Queen Elizabeth Hospital; Birmingham UK

9. The Queens University Belfast; Belfast UK

10. Haematology and Transplant Unit; Christie NHS Foundation Trust; Manchester UK

Funder